CorMedix Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-34673 CORMEDIX INC.(Exact Name of Registrant as Specified in Its Charter) 389 Interpace Pkwy, Suite 450, Parsippany, NJ07054 (908) 517-9500(Registrant’s Telephone Number, Including Area Code) 300 Connell Drive, Suite 4200, Berkeley Heights, NJ07922(Former Address of Principal Executive Offices)(Zip Code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging Growth Company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ The number of shares outstanding of the issuer’s common stock, as of May11, 2026 was 78,451,891. CORMEDIX INC. AND SUBSIDIARIES INDEX PagePART I FINANCIAL INFORMATION1Item 1.Unaudited Condensed Consolidated Financial Statements1Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20252Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months EndedMarch 31, 2026 and 20253Condensed ConsolidatedStatements of Changes in Stockholders’ Equity for the Three Months Ended March 31,2026 and 20254Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20255Notes to Unaudited Condensed Consolidated Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations23Item 3.Quantitative and Qualitative Disclosure About Market Risk29Item 4.Controls and Procedures29PART II OTHER INFORMATION31Item 1.Legal Proceedings31Item 1A.Risk Factors31Item 2.Unregistered Sales of Equity Securities and Use of Proceeds31Item 3.Defaults Upon Senior Securities31Item 4.Mine Safety Disclosure32Item 5.Other Information32Item 6.Exhibits33SIGNATURES34 PART IFINANCIAL INFORMATION Item 1. Unaudited Condensed Consolidated Financial Statements. CORMEDIX INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(In Thousands, Except Share Data) CORMEDIX INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSAND COMPREHENSIVE INCOME(In Thousands, Except Per Share Data)(Unaudited) CORMEDIX INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CHANGES INSTOCKHOLDERS’ EQUITY(In Thousands)(Unaudited) CORMEDIX INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In Thousands)(Unaudited) CORMEDIX INC. AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1 - Organization, Business and Basis of Presentation Organization and Business CorMedix Inc. ( “CorMedix” or the “Company”) was incorporated in the State of Delaware on July28, 2006. The Companyis a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases andconditions. Prior to the acquisition of Melinta Therapeutics, LLC ("Melinta") in August 2025 (the "merger"), the Company hadfocused on commercialization of its product, DefenCath® (taurolidine and heparin) in the United States. CorMedix launched theproduct commercially in 2024 in both the hospital inpatient and outpatient hemodialysis settings of care. The merger with Melinta expanded the Company’s team and commercial platform and increased the commercial portfoliowith six marketed, hospital- and clinic-focused infectious disease products, comprised of REZZAYO® (rezafungin for injection),MINOCIN® (minocycline) for Injection, VABOMERE® (meropenem and vaborbactam), KIMYRSA® (oritavancin), ORBACTIV®(oritavancin), BAXDELA® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL® (metoprololsuccina